flipper44,
I am with you on the ability to continue to accrue patient survival data and that they had minimal launch mfg capability a couple of yrs ago, really only in the US for commercial scale. Even though you would think survival data of all endpoint data would be the cleanest to continue to collect, I think NWBO decided they would face the market and the medical community with their stronger 5 yr data since their 5 yr data would not sow as strong on their K-M chart at the 3 yr timepoint. Post trial data collection is valid but not as valuable in the short term. This company is not Pfizer (yet), who would probably have done what you propose. You will notice there are a few small companies that start with much fanfare and capital and attention such as Moderna, but most startups are not as fortunate (not to mention the good fortune Moderna had with the onset of Covid).
Market Data 
Markets 
AI
